Manufacturing areas are deficient regarding the system for monitoring environmental conditions.
Inspection Record
Octapharma Produktionsgesellschaft Deutschland mbH. — FDA 483 Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
Procedures for deviations and corrective and preventive actions are not adequately established or implemented.
Cleaning validation program is inadequate.
A record as of the US FDA document published on 2026-10-26. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.